Compare CSQR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSQR | ARQT |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 2026 | 2020 |
| Metric | CSQR | ARQT |
|---|---|---|
| Price | $17.28 | $26.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $28.40 | ★ $37.00 |
| AVG Volume (30 Days) | 1.7M | ★ 3.0M |
| Earning Date | 11-20-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $16.12 | $42.98 |
| Revenue Next Year | $15.55 | $27.75 |
| P/E Ratio | ★ N/A | $874.00 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $15.58 | $19.30 |
| 52 Week High | $23.50 | $31.77 |
| Indicator | CSQR | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 55.98 |
| Support Level | $16.62 | $24.91 |
| Resistance Level | $18.67 | $28.05 |
| Average True Range (ATR) | 0.84 | 1.13 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 46.53 | 74.44 |
Csquare Inc is an enterprise digital infrastructure platform, owning and operating a geographically diverse portfolio of carrier-neutral data centers located across the United States, Canada and the United Kingdom. The company provides carrier-neutral colocation and interconnection services that provide infrastructure, including space, power, cooling systems, physical security, and interconnection capabilities, enabling customers to deploy and operate IT and network infrastructure. Its facilities support enterprise, network, cloud, and technology customers in the deployment and operation of IT and network infrastructure. The company generates the majority of its revenue from enterprise colocation services, which include fees for the licensing of cabinet space and power.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.